Antabio
PrivateLast Round
Series B
Dec 12, 2023
Total Funding Raised
$83.91M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments targeting drug-resistant infections caused by critical priority pathogens.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antabio Comparables
Compare Antabio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VenatoRx Pharmaceuticals | 90% | |
| Allecra Therapeutics | 86% | |
| Infex Therapeutics | 82% | |
Antabio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 12, 2023 | ||||
| Grant | Jan 6, 2022 | ||||
| Grant | Mar 16, 2021 | ||||
| Grant | Jan 2, 2020 | ||||
| Grant | Nov 13, 2019 | ||||
Series A | Jul 12, 2018 |
Antabio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AMR Action Fund | Series B |
| CARB-X | Grant |
| BNP Paribas Développement | Series B, Series A |
| iXO Private Equity | Series A |
| Turenne Groupe | Series B |
| Région Occitanie | Grant |
| Galia Gestion | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Monthly visitors grew 2413% MoM, from 46 to 1.2K.
- Mar 23, 2026
Collaborates with GARDP Foundation to accelerate early-stage antibiotic discovery.
Antabio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Antabio's valuation, stock price, and market status.